{"id":398150,"date":"2020-12-11T08:03:32","date_gmt":"2020-12-11T13:03:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398150"},"modified":"2020-12-11T08:03:32","modified_gmt":"2020-12-11T13:03:32","slug":"financial-calendar-for-zealand-pharma-in-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/financial-calendar-for-zealand-pharma-in-2021\/","title":{"rendered":"Financial calendar for Zealand Pharma in 2021"},"content":{"rendered":"
\n

\n Company announcement \u2013 No. 59 \/ 2020<\/strong>\n <\/p>\n

\n Copenhagen, December 11, 2020 \u2013 <\/em>Zealand Pharma A\/S (\u201cZealand\u201d) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the following dates for the company’s planned financial reporting in 2021.<\/p>\n

\n Deadline for submission of shareholder proposals to the Annual General Meeting<\/strong>
\n
March 3, 2021<\/p>\n

\n Annual Report 2020<\/strong>
\n
March 11, 2021<\/p>\n

\n Annual General Meeting<\/strong>
\n
April 15, 2021<\/p>\n

\n Interim Report First Quarter 2021<\/strong>
\n
May 12, 2021<\/p>\n

\n Interim Report First Half 2021<\/strong>
\n
August 12, 2021<\/p>\n

\n Interim Report Third Quarter 2021<\/strong>
\n
November 11, 2021<\/p>\n

Upon their release, the financial reports will be available at the Company\u2019s website, zealandpharma.com, where information relating to Zealand\u2019s Annual General Meeting 2021 will also be available in due course prior to the meeting.<\/p>\n

All dates are subject to NASDAQ deadlines and reporting requirements and are subject to change.<\/p>\n

# # #<\/p>\n

\n About Zealand Pharma A\/S <\/strong>
\n
Zealand Pharma A\/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand\u2019s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go\u00ae<\/sup>, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.<\/p>\n

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand\u2019s business and activities, please visit www.zealandpharma.com<\/u><\/a>. \u00a0<\/p>\n

\n For further information, please contact: <\/strong>\n <\/p>\n

Mads Kronborg
Head of Investor Relations & Communication
Phone: +45 5060 3707
Email: mkronborg@zealandpharma.com<\/u><\/a><\/p>\n

\n For U.S. Media<\/strong>
\n
David Rosen
Argot Partners
Phone: 212-600-1902
Email: media@zealandpharma.com<\/p>\n

\n

\n Attachment<\/strong>\n <\/p>\n